Home > SANTE - SCIENCES DE LA VIE > Industrie Pharmaceutique > Renovis: Premium Company ...
AUTRES RESSOURCES
 
AUTRES SECTEURS
 
TOUS NOS SECTEURS
 
Industrie Pharmaceutique > Etude de marché sectorielle
 Renovis: Premium Company Profile
€ 396,00
Editeur :
Datamonitor
Langue :
Anglais
Date de publication :
Décembre 2007
Taille du document :
45
Autres informations :
Description , Table des matières
 

Recevez cette publication aujourd'hui !
Plus d'information ?
+33 437 37 1637
 
Documents Publics
1,200,000 documents
Téléchargement illimités
 
Etudes Privées
50,000 rapports et études
Paiement à la piéce
 
1.Télécharger nos rapports publics

Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...

Nos documents publics sur le même théme (1)
Biotechnologies and Genetics market in USA
86 pages | Octobre 2006 | Anglais
 
 
   
Main focus: drug discovery,nanotechnology,biotechnology,...,...
Research focus: market size and estimates,market definition,
Geographic focus: usa,india,austria,france
   
Autres recherches sur le même thème
Rechercher d'autres rapports publics à télécharger
 
 
 
2. Rechercher d'autres rapports et études à commander

Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux


Rapports privés en relation
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded
365,00 €
 
 
OTC Cough and Cold Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year.
During the review period, the market grew by 9.4%, an
198,00 €
 
 
The Cardiovascular Outlook 1998-2010
186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998.
Market expansion is being driven by expanding prevalent populations in t
795,00 €
 
 
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur
1 200,00 €
 
 
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ
327,00 €
 
 
Patient Power Outlook 2001
152 pages | Juillet 2001 |
The increase in patient power witnessed over the last decade has been driven by developments in healthcare systems, patient advocacy activity, the increasing influence of the media in healthcare issue
955,00 €
 
 
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E
327,00 €
 
 
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
 
 
European Pharmaceutical Industry
35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus).
The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact
600,00 €
 
 
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph
795,00 €
 
 
 
Autres secteurs en relation
Rechercher d'autres rapports!
 
 
 
Présentation de l'étude de marché - Description & Table des matières
 Renovis: Premium Company Profile

Introduction

Renovis is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the areas of neurological and inflammatory diseases. Using its proprietary drug discovery capabilities in medicinal chemistry, cell biology and chemical screening libraries, the company is discovering and developing drug candidates internally as well as with strategic partners.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    Renovis, a small molecule drug discovering and developing company, has proprietary pipeline products such as P2X7 and P2X3 antagonists for pain that are in preclinical development stage. The company has collaborated with Pfizer for developing VR1 antagonist for the treatment of pain.

    During 2002-2006, the company recorded all of its revenues under collaborative agreements with. Pfizer for VR1 program and AstraZeneca for NXY-059, which was suspended in 2006 on failing to meet the primary end points.

    The total revenues increased from $5 million in 2003 to $10 million in 2006, primarily due to the increased upfront fees and milestone payments received from collaborative partners.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization


  •  

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 6
    Company Overview and Key Facts 6
    Business Description 7
    History 8
    Company Financials 10
    Stock Market Performance 10
    P&L 11
    Balance Sheet 14
    Cash Flow 14
    Business Segment Performance 15
    Products & Services 16
    Pipeline Products 16
    AC Forecast Product Sales 18
    Competitors and Strategic Business Relationships 19
    Key Competitors 19
    Key Suppliers 19
    Key Clients 20
    Shareholding Structure 21
    Strategy 22
    Company View 22
    Corporate Strategy 24
    SWOT Analysis 26
    Overview 26
    Strengths 27
    Weaknesses 28
    Opportunities 29
    Threats 31
    Value Chain Analysis 32
    Discovery and Product Development 33
    Scorecard 34
    Overview 34
    Scorecard Analysis 35
    Key Employees 36
    List of Key Employees 36
    Key Employee Biographies 37
    Financial and Operational Overview 43
    Financial and Operational Overview 43
    APPENDIX 45
    Ask the analyst 45
    Datamonitor consulting 45
    Disclaimer 45


    TABLE OF FIGURES
    Figure 1: Renovis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12


    TABLE OF TABLES
    Table 1: Renovis - Key Facts 6
    Table 2: Renovis - Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
    Table 3: Renovis - Key Events Impacting Share Price Performance 10
    Table 4: Renovis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
    Table 5: Renovis - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
    Table 6: Renovis – Balance Sheet, 2002-2006 ($ Mn) 14
    Table 7: Renovis – Cash Flow, 2002-2006 ($ Mn) 14
    Table 8: Renovis - Revenue Breakdown by Division, 2002-2006 ($ Mn) 15
    Table 9: Renovis - In-house Pipeline Products 16
    Table 10: Renovis - Collaboration Products 17
    Table 11: Renovis - Forecast Sales, 2006-2010 ($ Mn) 18
    Table 12: Renovis - Key Competitors 19
    Table 13: Renovis - Key Suppliers 19
    Table 14: Renovis – Key Clients 20
    Table 15: Renovis - Key Shareholders 21
    Table 16: Renovis - SWOT Analysis Summary 26
    Table 17: Renovis - Value Chain Analysis 32
    Table 18: Renovis - Scorecard 34
    Table 19: Renovis - Key Employees 36
    Table 20: Renovis - Financial and Operational Overview 43



    New Search:

    PPLSEN